Anthracycline-induced cardiomyopathy

Postgraduate Medicine

Volumn 120, Issue 4, 2008, Pages 67-72

  Simmons, Ashley ^a   Vacek, James L ^b   Meyers, David ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

Adriamycin ; Anthracycline; Cardiomyopathy; Cardiotoxicity; Daunorubicin; Doxorubicin

Indexed keywords

ACETYLCYSTEINE; ANTHRACYCLINE; ATENOLOL; CARVEDILOL; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROPOIETIN; LISINOPRIL; PLACEBO; PROBUCOL; PROPRANOLOL DERIVATIVE; RAZOXANE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; GENETIC SCREENING; HEART MUSCLE INJURY; HUMAN; INCIDENCE; LIPID PEROXIDATION; MEDICAL RESEARCH; NONHUMAN; PATIENT SELECTION; PROPHYLAXIS; REVIEW; SIDE EFFECT; CHEMICALLY INDUCED DISORDER;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; HUMANS;

EID: 58149184512     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.11.1940     Document Type: Review

References (52)

1. Jones R, Swanton C, Ewer M. Anthracycline cardiotoxicity. Expert OpinDrug Saf. 2006;5(6):791-809. (Pubitemid 44669494)
2. Kim K, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther. 2008;324(1):164-169. (Pubitemid 350294149)
3. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-2481. (Pubitemid 44901520)
4. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-2262. (Pubitemid 44855419)
5. Boucek RJ Jr, Stelle A, Miracle A, Atkinson J. Effects of angiotensin-converling enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3(4):319-329. (Pubitemid 38055999)
6. Simpson C, Herr H, Courville KA. Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. Clin J Oncol Nurs. 2004;8(5):497-501.
7. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125(1):47-58.
8. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Onc. 2004;22(24):4979-4990. (Pubitemid 46638624)
9. Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings: Prevention conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: executive summary. Circulation. 2000;101(1):111-116. (Pubitemid 30039085)
10. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754-3762. (Pubitemid 43739516)
11. Jungsuwadee P, Cole M, Sultana R, et al. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther. 2006;5(11):2851-2860. (Pubitemid 44849012)
12. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African-Americans. J Natl Med Assoc. 2004;96(2):196-199.
13. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231-1238.
14. Huang RS, Duan S, Kistner EO, et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008;68(9):3161-3168.
15. Oliveira PJ, Gonçalves L, Monteiro P, Providencia LA, Moreno AJ. Are the antioxidant properties of carvedilol important for protection of the cardiac mitochondria? Curr Vasc Pharmacol. 2005;3(2):147-158. (Pubitemid 40612986)
16. Topol E, Califf R, Prystowsky E, Thomas J, Thompson P. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippencott, Williams and Wilkins; 2007:1422.
17. Okumura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol. 2002;88(2):183-188. (Pubitemid 34223568)
18. Oliveira PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. 2004;200(2):159-168. (Pubitemid 39346022)
19. Floyd J, Morgan J, Perry M, et al. Cardiotoxicity of anthracycline-like chemotherapy agents. www.uptodate.com. Published May 20 2008. Assessed July 2008.
20. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49(5):330-352. (Pubitemid 46295436)
21. Deng S, Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):129-134. (Pubitemid 47339859)
22. Robert J. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Cardiovasc Toxicol. 2007;7(2):135-139. (Pubitemid 47339860)
23. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling, and failure. Cardiovasc Res. 2006;71(2):208-215. (Pubitemid 43913729)
24. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkiö M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21(12):2349-2356.
25. Lenihan DJ, Massey MR, Baysinger KB, et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail. 2007;13:S151.
26. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-2754. (Pubitemid 38737923)
27. Carver J, Shapiro C, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991-4008. (Pubitemid 47477279)
28. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53(6):461-470. (Pubitemid 26388387)
29. Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;7:9. (Pubitemid 46242723)
30. Hashimoto I, Ichida F, Miura M, et al. Automatic border detection identifies subclinical anthracycline cardiotoxicity in children with malignancy. Circulation. 1999;99(18):2367-2370. (Pubitemid 29218229)
31. Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 1986;58(7):607-613. (Pubitemid 16023529)
32. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress echocardiography. Eur J Pediatr. 2001;160:607-610. (Pubitemid 32939431)
33. Rohde LE, Baldi A, Weber C, et al. Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity. Int J Cardiovasc Imaging. 2007;23(2):185-191.
34. Tjeerdsma G, Meinardi MT, van Der Graaf WT, et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiography variables. Heart. 1999;81(4):419-423. (Pubitemid 29167133)
35. Bu'Lock FA, Mott MG, Oakhill A, Martin RP. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child. 1996;75(5):416-422. (Pubitemid 26405682)
36. Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr. 2003;162(10):690-696. (Pubitemid 37255501)
37. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709. (Pubitemid 34567375)
38. Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med. 1981;94(4 part 1):430-435. (Pubitemid 11103937)
39. DeWolf D, Suys B, Verhaaren H, Matthys D, Taeymans Y. Low-dose dobutamine stress echocardiography in children and young adults. Am J Cardiol. 1998;81(7):895-901. (Pubitemid 28204643)
40. Nousiainen T, Jantunen D, Vanninen D, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697-1700. (Pubitemid 34712910)
41. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987;9(1):184-188. (Pubitemid 17219564)
42. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629-2636. (Pubitemid 46179451)
43. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol. 1992;20(1):62-69.
44. Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniëls O. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ultrasound Med Biol. 2000;26(7):1099-1108.
45. Nagy AC, Tolnay E, Nagykálnai T, Forster T. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI. Neoplasma. 2006;53(6):511-517. (Pubitemid 46133513)
46. Nagy AC, Cserép Z, Tolnay E, Nagykálnai T, Forster T. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res. 2008;14(1):69-77.
47. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. New Engl J Med. 1998;339(13):900-905. (Pubitemid 28446849)
48. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992;70(1):73-77.
49. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60(6):1213-1218. (Pubitemid 17152896)
50. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-314.
51. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109-1118. (Pubitemid 18101522)
52. Bien S, Riad A, Ritter CA, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res. 2007;67(21):10428-10435. (Pubitemid 350070818)